The growing recognition of obesity as a chronic disease requiring sustained intervention will drive demand for structured treatment pathways and outcomes-based reimbursement arrangements
In contrast to generic medicines which are exact copies of chemically synthesised branded drugs, biosimilars closely resemble the structure and function of their reference product and are produced in modified living organisms like yeast and bacteria
& Horowitz, M
Furthermore, those who died during followup could have been misclassified, that is, as nonadherent
Clinical scenarios warranting consideration of GLP-1 therapy include: Type 2 diabetes management : Per ADA 2024 Standards of Care, GLP-1 RAs may be considered as initial therapy in patients with established atherosclerotic cardiovascular disease (ASCVD), high ASCVD risk, chronic kidney disease (CKD), or heart failure, or as add-on therapy when glycemic targets aren't met Established cardiovascular disease : Several GLP-1 receptor agonists have demonstrated cardiovascular risk reduction in patients with type 2 diabetes and established ASCVD Chronic kidney disease : While SGLT2 inhibitors are generally prioritized for CKD with type 2 diabetes when eGFR allows, GLP-1 RAs may provide complementary benefits Obesity with complications : When lifestyle interventions produce insufficient weight loss in patients with obesity-related comorbidities Important safety considerations include: Contraindications : Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
